Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NovoCure Limited - Ordinary Shares (NQ:NVCR)

12.71 +2.21 (+21.05%)
Streaming Delayed Price Updated: 2:51 PM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about NovoCure Limited - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Novocure to Participate in Upcoming Investor Conferences
From Novocure
Via Business Wire
News headline image
Novocure Hosts U.S. Sen. Maggie Hassan at Company’s Portsmouth Facility
From Novocure
Via Business Wire
News headline image
Novocure Reports Second Quarter 2022 Financial Results
From Novocure
Via Business Wire
News headline image
Novocure Announces Recipients of 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
From Novocure
Via Business Wire
News headline image
Novocure to Report Second Quarter 2022 Financial Results
From Novocure
Via Business Wire
News headline image
Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields Together with KEYTRUDA® for Patients with First-Line Stage III Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
News headline image
Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer
From Novocure
Via Business Wire
News headline image
Novocure Announces Clinical Collaboration with MSD on a Registrational-Intent Study to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Newly Diagnosed Glioblastoma
From Novocure
Via Business Wire
News headline image
Novocure Reports First Quarter 2022 Financial Results
From Novocure
Via Business Wire
News headline image
Novocure Hosts Ceremonial Groundbreaking with New Hampshire Governor Chris Sununu
From Novocure
Via Business Wire
News headline image
Novocure Announces 19 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2022 Suggesting Broad Applicability of Tumor Treating Fields
From Novocure
Via Business Wire
News headline image
Novocure to Report First Quarter 2022 Financial Results
From Novocure
Via Business Wire
News headline image
Updated 2-THE-TOP Data Suggest Improvements in Progression-Free Survival, Overall Survival Compared to Matched-Control Patients from EF-14 Trial
From Novocure
Via Business Wire
News headline image
Novocure Announces Favorable Recommendation to Continue the Phase 3 Pivotal INNOVATE-3 Study of Tumor Treating Fields in Ovarian Cancer
From Novocure
Via Business Wire
News headline image
Novocure Founder Yoram Palti Wins 2022 Israel Prize in Entrepreneurship and Technological Innovation
From Novocure
Via Business Wire
News headline image
Novocure’s General Counsel Resigns After 10 Years of Service
From Novocure
Via Business Wire
News headline image
New Data Finds Tumor Treating Fields Initiates Downstream Anti-Tumor Response
From Novocure
Via Business Wire
News headline image
Novocure Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update
From Novocure
Via Business Wire
News headline image
Novocure Announces Preliminary Full Year and Fourth Quarter 2021 Net Revenues and Provides Company Update
From Novocure
Via Business Wire
News headline image
Novocure to Participate in the 40th Annual J.P. Morgan Healthcare Conference
From Novocure
Via Business Wire
News headline image
Novocure Signs Agreement to Acquire and Construct Building in Downtown Portsmouth, New Hampshire
From Novocure
Via Business Wire
News headline image
Novocure Announces 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
From Novocure
Via Business Wire
News headline image
Novocure to Participate in Two Upcoming Investor Conferences
From Novocure
Via Business Wire
News headline image
Novocure Announces Last Patient Enrolled in Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-small Cell Lung Cancer
From Novocure
Via Business Wire
News headline image
2-THE-TOP Phase 2 Trial Reports Positive Top-Line Results in Newly Diagnosed Glioblastoma
From Novocure
Via Business Wire
News headline image
Novocure Announces 31 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2021 Annual Meeting
From Novocure
Via Business Wire
News headline image
Novocure Reports Third Quarter 2021 Financial Results and Provides Company Update
From Novocure
Via Business Wire
News headline image
Novocure Announces Last Patient Enrolled in Phase 3 Pivotal INNOVATE-3 Trial of Tumor Treating Fields in Ovarian Cancer
From Novocure
Via Business Wire
News headline image
Novocure Announces 15 Presentations at the American Society for Radiation Oncology 2021 Annual Meeting
From Novocure
Via Business Wire
News headline image
Novocure and Zai Lab Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China
From Novocure
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.